Prelude Therapeutics Inc (NASDAQ: PRLD) is -70.96% lower on its value in year-to-date trading and has touched a low of $0.80 and a high of $6.80 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PRLD stock was last observed hovering at around $1.30 in the last trading session, with the day’s loss setting it -0.06%.
Currently trading at $1.24, the stock is 26.15% and 2.09% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.43 million and changing -4.62% at the moment leaves the stock -64.36% off its SMA200. PRLD registered -69.46% loss for a year compared to 6-month loss of -67.28%. The firm has a 50-day simple moving average (SMA 50) of $1.22886 and a 200-day simple moving average (SMA200) of $3.495265.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 28.21% gain in the last 1 month and extending the period to 3 months gives it a -43.64%, and is 38.44% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 27.18% over the week and 13.14% over the month.
Prelude Therapeutics Inc (PRLD) has around 128 employees, a market worth around $68.24M and $3.00M in sales. Profit margin for the company is -4383.90%. Distance from 52-week low is 55.66% and -81.76% from its 52-week high. The company has generated returns on investments over the last 12 months (-76.53%).
The EPS is expected to grow by 12.13% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Prelude Therapeutics Inc (PRLD) Top Institutional Holders
101.0 institutions hold shares in Prelude Therapeutics Inc (PRLD), with institutional investors hold 93.76% of the company’s shares. The shares outstanding are 42.18M, and float is at 21.88M with Short Float at 13.97%. Institutions hold 84.98% of the Float.
The top institutional shareholder in the company is ORBIMED ADVISORS LLC with over 10.91 million shares valued at $41.56 million. The investor’s holdings represent 14.4043% of the PRLD Shares outstanding. As of 2024-06-30, the second largest holder is BAKER BROS. ADVISORS LP with 10.12 million shares valued at $38.57 million to account for 13.3673 of the shares outstanding. The other top investors are DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) which holds 4.13 million shares representing 5.4571% and valued at over $15.75 million, while BOXER CAPITAL, LLC holds 3.3911 of the shares totaling 2.57 million with a market value of $9.79 million.
Prelude Therapeutics Inc (PRLD) Insider Activity
The most recent transaction is an insider purchase by Lim Bryant David, the company’s CLO, Interim CFO, Corp Sec. SEC filings show that Lim Bryant David bought 25,000 shares of the company’s common stock on Dec 19 ’24 at a price of $0.91 per share for a total of $22638.0. Following the purchase, the insider now owns 27400.0 shares.
Prelude Therapeutics Inc disclosed in a document filed with the SEC on Dec 18 ’24 that Vaddi Krishna (CEO) bought a total of 100,000 shares of the company’s common stock. The trade occurred on Dec 18 ’24 and was made at $0.93 per share for $93210.0. Following the transaction, the insider now directly holds 1.17 million shares of the PRLD stock.
Still, SEC filings show that on Dec 19 ’24, Vaddi Krishna (CEO) acquired 6,888 shares at an average price of $0.89 for $6116.0. The insider now directly holds 127,553 shares of Prelude Therapeutics Inc (PRLD).
